ABSTRACT

Purpose: To date, there are no promising treatments for gastric carcinoma with peritoneal metastasis. Some researchers have suggested a survival benefit of gastrectomy in select patients. This study investigated the survival of gastric carcinoma patients with stand-alone peritoneal metastasis according to the type of treatment modality.

Materials and Methods: We reviewed the data of 132 patients with gastric carcinoma and stand-alone peritoneal metastasis. We performed gastrectomy when the primary tumor was deemed resectable and systemic chemotherapy was administered. We analyzed patient survival according to the type of treatment, and the prognostic value of gastrectomy was evaluated in univariate and multivariate models.

Results: Among all patients, 70 underwent gastrectomy plus chemotherapy, 20 underwent gastrectomy alone, 36 underwent chemotherapy alone, and 6 received supportive care. The median patient survival was 13 months. Patients who underwent gastrectomy had significantly longer survival than those who did not undergo gastrectomy (14 vs. 8 months, P<0.001). Patients who received chemotherapy showed significantly longer survival than those who did not (13 vs. 7 months, P=0.032). Patients who underwent gastrectomy plus chemotherapy showed better survival than those who underwent other treatments. In multivariate analysis, gastrectomy was found to be an independent prognostic factor (hazard ratio, 0.52; 95% confidence interval, 0.33–0.82) in addition to chemotherapy.

Conclusions: Our study showed that patients who underwent gastrectomy plus chemotherapy had the best survival. Although the survival benefit of gastrectomy remains uncertain, it is a favorable prognostic indicator in patients with stand-alone peritoneal metastasis.

Keywords: Stomach neoplasm; Peritoneal metastasis; Gastrectomy

INTRODUCTION

Despite the decrease in global incidence, gastric carcinoma is the fifth most common cancer and the third leading cause of cancer-related death worldwide [1]. With advances in the treatment of gastric carcinoma, there are various multidisciplinary treatment options available such as minimally invasive surgery, endoscopic treatment, molecular targeting agents, and immunotherapy [2,3]. Curative surgery, including gastric resection and regional...
lymph node dissection, remains the mainstay of treatment for gastric carcinoma. Patients with early stage disease have a ≥90% survival rate after surgery alone [4]. However, systemic chemotherapy is the only treatment option for metastatic gastric carcinoma, and the prognosis is dismal, with a median survival of 11–13 months [5].

Peritoneal metastasis is the most common form of metastasis in gastric carcinoma. The post chemotherapy median survival of gastric carcinoma patients with peritoneal metastasis is approximately 10 months [6]. Some researchers have reported an improvement in patient survival with extensive peritonectomy combined with hyperthermic intraperitoneal chemotherapy [7,8]. However, this treatment has not been widely accepted due to high morbidity and mortality. Recently, a conversion surgery that combined induction chemotherapy and a second surgery was introduced as a new treatment modality for patients with peritoneal metastasis. Some studies reported a good response in peritoneal metastasis and an improvement in the curative resection rate through systemic [9] or intraperitoneal induction chemotherapy [10].

The survival benefit of gastrectomy for gastric carcinoma with peritoneal metastasis is controversial. Some researchers have reported improved survival with gastrectomy in patients with peritoneal metastasis [11]. However, other studies reported no significant benefit of gastrectomy [12,13]. In a large randomized controlled trial (RCT; REGATTA trial), gastrectomy did not improve survival compared to chemotherapy alone in metastatic gastric carcinoma [14]. However, this study included a heterogeneous population with various types of metastases, and the effect of gastrectomy could not be assessed in patients with peritoneal metastasis alone. In our institution, we performed palliative gastrectomy when the primary tumor was deemed resectable and administered systemic chemotherapy for stand-alone peritoneal metastasis. In this study, we aimed to analyze patient survival according to the type of treatment administered and investigated the prognostic value of gastrectomy in gastric carcinoma with stand-alone peritoneal metastasis.

MATERIALS AND METHODS

Patients
Using the data available in our gastric cancer database, we identified 3,617 patients who underwent surgery for gastric carcinoma between and 2009–2013 at our institution (Chonnam National University Hwasun Hospital [CNUHH], Hwasun, Korea). After excluding 124 patients for the presence of other malignancies (n=31), recurrent gastric cancer (n=42), or incomplete data in the database (n=51), we retrospectively reviewed the data of 3,493 patients who underwent surgery for primary gastric carcinoma. The inclusion criterion was the presence of peritoneal metastases alone. We enrolled 132 patients who met this criterion (Fig. 1). In our institution, we performed palliative gastrectomy when the primary tumor was deemed surgically resectable, and systemic chemotherapy was administered to these patients. After surgery, the decision of chemotherapy was made at the discretion of the oncologists, depending on the patient’s condition. Patients with a poor general condition who were unfit for subsequent chemotherapy received conservative care only. Therefore, we divided patients into the following 4 groups according to the type of treatment: 1) gastrectomy plus chemotherapy, 2) gastrectomy alone, 3) chemotherapy alone, and 4) supportive care only. We investigated the patient survival according to treatment received.
Patients underwent preoperative staging using endoscopy with biopsy and multidetector computed tomography (CT). Other imaging modalities such as chest CT, liver magnetic resonance imaging, or positron emission tomography-CT scanning were used as appropriate. According to predefined diagnostic criteria, we made a clinical diagnosis of tumor invasion and lymph node metastasis [15]. After the surgery, the patients received fluoropyrimidine-based (5-FU, S-1, or capecitabine) and platinum-based (cisplatin or oxaliplatin) chemotherapy with or without trastuzumab. This study was performed after obtaining approval from the Institutional Review Board at CNUHH (CNUHH-2020-166), which waived the requirement for informed consent from patients.

Data collection and definitions

Patient clinical and pathological data were retrieved from a prospectively constructed gastric cancer database. We collected data on the following variables: demographics (age, sex, body mass index [BMI], comorbidities, medical history, nutritional status, and physiologic status), preoperative examination (clinical tumor stage, tumor markers, and other laboratory findings), operative results (gastric resection, reconstruction, lymph node dissection, combined resection, operating time, and operative bleeding), pathologic results (histologic classification, tumor location, tumor size, and pathological stage), and postoperative outcomes (diet start, hospital stay, morbidity, and mortality).

The pathologic tumor stage was based on the eighth edition of the American Joint Committee on Cancer tumor-node-metastasis classification of gastric carcinoma [16]. Postoperative morbidity and mortality were defined as complications or deaths within 30 postoperative days. Postoperative complications were classified as local or systemic according to the site of development. The severity of complications was graded according to the Clavien-Dindo classification of surgical complications [17].
The primary outcome of this study was overall survival. Overall survival was defined as the time from surgery to death from any cause. To calculate survival status, the patients were followed up until December 2017. Survival data were obtained from the National Cancer Registry and medical records. The median follow-up period was 13 months (range, 1–94 months).

**Statistical analysis**

Data were expressed as mean±standard deviation or number (%). Student’s t-test was used for continuous variables, and the \( \chi^2 \) test or Fisher’s exact test was used for categorical variables. The Kaplan-Meier method and log-rank test were used for the survival analysis. The Cox proportional hazards model was used for multivariate analysis of prognostic factors. Statistical analysis was performed using IBM SPSS Statistics for Windows, version 23.0 (IBM Corp., Armonk, NY, USA). Two-sided P-values of <0.05 were considered statistically significant.

**RESULTS**

The clinicopathological characteristics of the patients are shown in **Table 1**. There were 84 male and 48 female patients, with a mean age of 59.6±14.9 years. Gastrectomy was

| Table 1. Patient characteristics |
|----------------------------------|
| **Variables**                    | **Patients (n=132)** |
| Age (yr)                          | 59.6±14.9 |
| Sex                               |          |
| Male                              | 84 (63.6) |
| Female                            | 48 (36.4) |
| Body mass index (kg/m²)           | 21.6±3.3 |
| Comorbidity                       | 71 (53.8) |
| ASA status                        |          |
| 1                                 | 48 (36.4) |
| 2                                 | 73 (55.3) |
| 3                                 | 11 (8.3)  |
| Tumor location                    |          |
| Lower                             | 52 (39.4) |
| Middle                            | 31 (23.5) |
| Upper                             | 23 (17.4) |
| Whole stomach                     | 26 (19.7) |
| Clinical T stage                  |          |
| cT2                               | 8 (6.1)  |
| cT3                               | 26 (19.7) |
| cT4a                              | 78 (59.1) |
| cT4b                              | 20 (15.2) |
| Clinical N stage                  |          |
| cN0                               | 23 (17.4) |
| cN1                               | 37 (28.0) |
| cN2                               | 35 (26.5) |
| cN3                               | 37 (28.0) |
| Operation                         |          |
| Distal gastrectomy                | 42 (31.8) |
| Total gastrectomy                 | 48 (36.4) |
| No resection                      | 42 (31.8) |
| Combined organ resection           | 31 (23.5) |
| Treatment modalities              |          |
| Gastrectomy plus chemotherapy     | 70 (53.0) |
| Gastrectomy alone                 | 20 (15.2) |
| Chemotherapy alone                | 36 (27.3) |
| Supportive care                   | 6 (4.5)  |

Data are shown as mean±standard deviation or number (%). ASA = American Society of Anesthesiologists physiologic status.
performed in 90 (68.2%) patients, including distal (n=42) and total gastrectomy (n=48). Combined organ resection was performed in 31 patients (23.5%). Chemotherapy was administered to 106 patients (80.3%). Overall, 70 (53.0%) patients underwent gastrectomy plus chemotherapy, 20 (15.2%) patients underwent gastrectomy alone, 36 (27.3%) patients received chemotherapy alone, and 6 (4.5%) patients received supportive care only.

**Short-term outcomes of gastrectomy in peritoneal metastasis**

Table 2 shows the data of short-term surgical outcomes in 90 patients who underwent non-curative gastrectomy for peritoneal metastasis compared with patients who underwent conventional curative gastrectomy (n=3,344). The mean age of patients with conventional curative gastrectomy was 61.3±11.9 years, and the mean BMI was 23.6±3.2 kg/m². Of all the patients undergoing curative gastrectomy, 57.8% (n=1,933) had comorbidities. Distal and total gastrectomy was performed in 2020 (81.3%) and 603 (18.0%) patients, respectively. Compared with the non-curative gastrectomy group, the curative gastrectomy group showed a significantly higher BMI (23.6% vs. 21.5%, P<0.001) and lower frequency of total gastrectomy (18.0% vs. 53.3%, P<0.001).

The incidence of local complications was higher after non-curative gastrectomy (23.3% vs. 13.8%, P=0.014). However, only paralytic ileus showed a significantly higher incidence among local complications, while other complications were similar. The incidence of grade ≥3 complications or mortality did not significantly differ between the 2 groups, neither did the postoperative length of hospital stay.

**Survival according to treatment**

During follow-up, 128 of 132 patients died. The median overall survival in all patients was 13 months (95% confidence interval [CI], 11.5–14.5). The 1-year-and 2-year survival rates were 52% and 16%, respectively.

**Fig. 2** shows the Kaplan-Meier survival curves according to the type of treatment. With regard to gastrectomy, patients who underwent gastrectomy showed significantly longer survival than those without gastrectomy. The median survival rates of patients with and without...
gastrectomy were 14 and 8 months, respectively (log-rank P<0.001) (Fig. 2A). Patients who received chemotherapy also showed significantly longer survival than those who did not (Fig. 2B). The median survival rates of patients with and without chemotherapy were 13 and 7 months, respectively (log-rank P=0.032). When survival rates were compared among groups with different treatment modalities, patients who underwent gastrectomy plus chemotherapy showed better survival (median survival, 15 months; 95% CI, 12.5–17.5) than those who underwent gastrectomy or chemotherapy alone (Fig. 3).

Univariate and multivariate analyses of prognostic factors
To determine the prognostic factors, we examined patient survival according to demographic factors (age, sex, malnutrition, and comorbidity), tumor factors (clinical T and N stage, ascites, serum carcinoembryonic antigen, and carbohydrate antigen 19-9 level), and
treatment factors (gastrectomy and chemotherapy) (Table 3). None of the demographic factors was associated with survival. Among the tumor factors, clinical T stage (P=0.009), clinical N stage (P=0.002), and the presence of ascites (P=0.001) were significantly associated with survival. Among the treatment factors, gastrectomy (P<0.001) and chemotherapy (P=0.036) significantly improved patient survival. Multivariate analysis of these factors revealed that clinical N stage (cN0-2 vs. cN3; hazard ratio [HR], 1.53; 95% CI, 1.03–2.29), gastrectomy (HR, 0.52; 95% CI, 0.33–0.82), and chemotherapy (HR, 0.53; 95% CI, 0.34–0.84) were independent prognostic factors in gastric carcinoma with peritoneal metastasis.

DISCUSSION

The survival benefit of gastrectomy for gastric carcinoma with peritoneal metastasis remains uncertain. In this study, we investigated the long-term survival of gastric carcinoma with stand-alone peritoneal metastasis according to the type of treatment received. We found that patients who underwent gastrectomy followed by chemotherapy showed better survival than those who underwent other treatments. Furthermore, gastrectomy is an independent prognostic factor in these patients. The survival benefit of gastrectomy for stand-alone peritoneal metastasis in gastric carcinoma requires extensive validation. However, our results indicate that gastrectomy is a favorable factor for predicting longer survival in gastric carcinoma with stand-alone peritoneal metastasis.

Several studies have investigated the survival benefits of gastrectomy in gastric carcinoma with peritoneal metastasis. In an analysis of 747 patients with peritoneal metastasis, patients showed significantly longer survival after gastrectomy, and gastrectomy was an independent prognostic factor in multivariate analysis [18]. Similarly, Geng et al [19] and Yang et al [20], showed that gastrectomy significantly improved the survival of patients with peritoneal metastasis. Li et al [21]. used propensity score matching to analyze 5,640 metastatic gastric cancer patients identified from the Surveillance, Epidemiology, and End Results registry. The authors found that gastrectomy was associated with improved survival in patients who had a single metastasis only.

However, some studies have reported contrasting results. Tokunaga et al [12]. reported that chemotherapy improved survival in patients with peritoneal metastasis, but gastrectomy...
did not. Similarly, Chen et al. [13] showed that gastrectomy improved survival in patients with distant lymph node metastasis or liver metastasis, but not in patients with peritoneal metastasis. One RCT investigated the survival benefit of gastrectomy in patients with metastatic gastric carcinoma [14]. This study failed to demonstrate the survival benefit of gastrectomy plus chemotherapy compared to that of chemotherapy alone. However, this study included various types of metastases, and the survival benefit of gastrectomy for stand-alone peritoneal metastasis could not be adequately assessed. Therefore, further investigations are needed to determine the survival benefit of gastrectomy in patients with peritoneal metastasis alone.

Many studies have suggested that the extent of peritoneal metastasis is a major determinant of survival in patients undergoing gastrectomy for peritoneal metastasis. Hioki et al. [22] analyzed prognostic factors in 101 patients who underwent gastrectomy for peritoneal metastasis. The authors showed that there was a significant difference in survival depending on the extent of peritoneal metastasis. Similarly, Gretschel et al. [23] reported that gastrectomy improved survival when patients had only a few peritoneal metastases to the adjacent peritoneum. Similar results were reported in many other studies, suggesting the survival benefit of gastrectomy in patients with a minimum extent of peritoneal metastasis [18-20], indicating that the decision for gastrectomy needs to be guided by the degree of peritoneal metastasis.

Systemic chemotherapy is the mainstay of treatment for metastatic gastric carcinoma. Theoretically, gastrectomy reduces tumor volume, which, in turn, can increase chemotherapy efficacy and provide immunologic benefits by reducing tumor-associated cytokines and immunosuppression [24]. Therefore, gastrectomy is expected to exert a synergic effect when combined with subsequent chemotherapy in metastatic gastric carcinoma. Nie et al. [18] demonstrated improvement in survival with gastrectomy combined with chemotherapy, but not with gastrectomy alone. Furthermore, gastrectomy significantly improved survival in a subgroup of patients undergoing chemotherapy. Geng et al. [19] reported that patients who underwent gastrectomy plus chemotherapy showed better survival than those who underwent either gastrectomy or chemotherapy alone. Our study showed that patients who underwent gastrectomy combined with chemotherapy showed better survival (median, 15 months) than those who underwent other treatments.

Despite the possible synergic effect of gastrectomy with chemotherapy, it is also concerning that gastrectomy may negatively affect compliance with subsequent chemotherapy. In the REGATTA trial, the gastrectomy group received fewer chemotherapy cycles than the chemotherapy alone group, especially in patients undergoing total gastrectomy [11]. This impaired chemotherapy compliance was thought to be responsible for poor survival in this patient group. Our study showed that compliance with chemotherapy was not significantly affected by gastrectomy, as indicated by 78% in the gastrectomy group and 85% in the no gastrectomy group (P=0.342). The impact of gastrectomy on compliance with subsequent chemotherapy may require further investigation. However, we observed that most patients who underwent gastrectomy underwent subsequent chemotherapy without significant debilitation.

This study had some limitations. First, selection bias was inevitable because of the retrospective nature of this study. Therefore, better survival with gastrectomy may be associated with a relatively better performance status or less tumor burden in patients undergoing gastrectomy. Although our study demonstrated gastrectomy as an independent
prognostic factor, the survival benefit of gastrectomy may require extensive investigation. Second, we could not assess patient survival after gastrectomy according to the extent of peritoneal metastasis. This may be helpful in defining the indication and guidelines for gastrectomy in cases with stand-alone peritoneal metastasis. Third, this study included only patients who underwent surgery for peritoneal metastasis, which may limit the generalizability of the study results. Finally, patients with missing data were excluded from the present study. However, the number of patients missing data was relatively low because of the prospectively maintained database.

In conclusion, the present study showed that gastrectomy combined with chemotherapy resulted in the best survival in gastric carcinoma with stand-alone peritoneal metastasis. We found that gastrectomy was an independent favorable prognostic factor in addition to chemotherapy. However, the survival benefit of gastrectomy may require further validation in patients with peritoneal metastasis alone.

REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.
2. Ilson DH. Advances in the treatment of gastric cancer. Curr Opin Gastroenterol 2018;34:465-468.
3. Russo AE, Strong VE. Gastric cancer etiology and management in Asia and the West. Annu Rev Med 2019;70:353-367.
4. Katai H, Ishikawa T, Akazawa K, Isobe Y, Miyashiro I, Oda I, et al. Five-year survival analysis of surgically resected gastric cancer cases in Japan: a retrospective analysis of more than 100,000 patients from the nationwide registry of the Japanese Gastric Cancer Association (2001–2007). Gastric Cancer 2018;21:144-154.
5. Wagner AD, Syn NL, Moehler M, Grothe W, Yong WP, Tai BC, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2017;8:CD004064.
6. Shirao K, Boku N, Yamada Y, Yamaguchi K, Doi T, Goto M, et al. Randomized phase III study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106). Jpn J Clin Oncol 2013;43:972-980.
7. Yang XJ, Huang CQ, Suo T, Mei LJ, Yang GL, Cheng FL, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol 2011;18:1575-1581.
8. Rudloff U, Langan RC, Mullinax JE, Beane JD, Steinberg SM, Beresnev T, et al. Impact of maximal cytoreductive surgery plus regional heated intraoperative chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial. J Surg Oncol 2014;110:275-284.
9. Okabe H, Ueda S, Ohama K, Hosogi H, Sakai Y. Induction chemotherapy with S-1 plus cisplatin followed by surgery for treatment of gastric cancer with peritoneal dissemination. Ann Surg Oncol 2009;16:3272-3236.
10. Ishigami H, Yamaguchi H, Yamashita H, Asakage M, Kitayama J. Surgery after intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology findings. Gastric Cancer 2017;20:128-134.
11. Sun J, Song Y, Wang Z, Chen X, Gao P, Xu Y, et al. Clinical significance of palliative gastrectomy on the survival of patients with incurable advanced gastric cancer: a systematic review and meta-analysis. BMC Cancer 2013;13:577.
12. Tokunaga M, Terashima M, Tanizawa Y, Bando E, Kawamura T, Yasui H, et al. Survival benefit of palliative gastrectomy in gastric cancer patients with peritoneal metastasis. World J Surg 2012;36:2637-2643.

13. Chen S, Li YF, Feng XY, Zhou ZW, Yuan XH, Chen YB. Significance of palliative gastrectomy for late-stage gastric cancer patients. J Surg Oncol 2012;106:862-871.

14. Fujitani K, Yang HK, Mizusawa J, Kim YW, Terashima M, Han SU, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol 2016;17:309-318.

15. Kim JW, Shin SS, Heo SH, Lim HS, Lim NY, Park YK, et al. The role of three-dimensional multidetector CT gastrography in the preoperative imaging of stomach cancer: emphasis on detection and localization of the tumor. Korean J Radiol 2015;16:80-89.

16. Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, et al. AJCC Cancer Staging Manual. 8th ed. New York (NY): Springer, 2017.

17. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004;240:205-213.

18. Nie RC, Chen S, Yuan SQ, Chen XJ, Chen YM, Zhu BY, et al. Significant role of palliative gastrectomy in selective gastric cancer patients with peritoneal dissemination: a propensity score matching analysis. Ann Surg Oncol 2016;23:3956-3963.

19. Geng X, Liu H, Lin T, Hu Y, Chen H, Zhao L, et al. Survival benefit of gastrectomy for gastric cancer with peritoneal carcinomatosis: a propensity score-matched analysis. Cancer Med 2016;5:2781-2791.

20. Yang K, Liu K, Zhang WH, Lu ZH, Chen XZ, Chen XL, et al. The value of palliative gastrectomy for gastric cancer patients with intraoperatively proven peritoneal seeding. Medicine (Baltimore) 2015;94:e1051.

21. Li Q, Zou J, Jia M, Li P, Zhang R, Han J, et al. Palliative gastrectomy and survival in patients with metastatic gastric cancer: a propensity score-matched analysis of a large population-based study. Clin Transl Gastroenterol 2019;10:1-8.

22. Hioki M, Gotohda N, Konishi M, Nakagohri T, Takahashi S, Kinoshita T. Predictive factors improving survival after gastrectomy in gastric cancer patients with peritoneal carcinomatosis. World J Surg 2010;34:555-562.

23. Gretschel S, Siegel R, Estévez-Schwarz L, Hünerbein M, Schneider U, Schlag PM. Surgical strategies for gastric cancer with synchronous peritoneal carcinomatosis. Br J Surg 2006;93:1530-1535.

24. Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol 2013;14:e218-e228.